AbbVie and Neomorph Announce Collaboration to Develop …
4 days ago · "Protein degraders represent a groundbreaking advancement in the field of drug discovery and at AbbVie we are committed to advancing this technology forward," said Steven …
AbbVie Completes Acquisition of Nimble Therapeutics
4 days ago · For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward …
AbbVie Completes Acquisition of Nimble Therapeutics - PR …
3 days ago · News provided by AbbVie Jan 23, 2025, 09:16 ET. Share this article. Share to X. Share this article. Share to X. Acquisition adds potential novel oral peptide IL23R inhibitor for …
AbbVie News Center - News
3 days ago · AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat …
AbbVie and Neomorph Announce Collaboration to Develop …
3 days ago · News provided by AbbVie Jan 23, 2025, 09:00 ET. Share this article. Share to X. Share this article. Share to X. Collaboration leverages AbbVie's expertise in oncology and …
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third …
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
Nov 11, 2024 · AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with …
AbbVie lifts 2024 profit forecast, shares hit record high
Jul 25, 2024 · AbbVie increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street expectations, …
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · (Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates …
AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada
Oct 28, 2024 · AbbVie is expanding its neuroscience portfolio as it faces a 33% drop in sales of its blockbuster arthritis drug Humira.